Establishment Labs Holdings, Inc. (ESTA)

Establishment Labs Holdings, Inc. stock has experienced fluctuations in the past six months. As of March 24, 2026, the share price was $58.06, a 39.70% increase year-over-year, but it has recently fallen -16.03% compared to the previous week and -30.78% over the last month as of March 27, 2026. The 52-week range has been between $26.55 and $83.31. The company reported its Fourth Quarter and Full Year 2025 financial results on February 24, 2026, beating EPS and revenue forecasts, but the stock fell 10.62% in pre-market trading. A leadership transition was also announced on February 24, 2026. The next earnings report is expected on May 11, 2026.

Demand for Establishment Labs Holdings, Inc.'s products exhibits seasonality. The fourth quarter is typically the strongest quarter for breast augmentation, while the third quarter is generally a seasonally low period. Despite this, the company reported a sequential increase in U.S. revenue in Q3 2025. The company benefits from strong, sustained demand in the global aesthetics market.

Establishment Labs Holdings, Inc. is a medical technology company focused on women's health, specifically in breast aesthetics and reconstruction. The company designs, develops, manufactures, and markets medical devices and aesthetic products, including silicone-filled breast and body-shaping implants under the Motiva Implants brand. The company operates within the Healthcare sector and its primary industry is Therapeutic Devices or Medical Devices.

Establishment Labs has a global geographic footprint, distributing its products through direct sales to medical distributors, physicians, hospitals, and clinics. Its geographical segments include Europe, Latin America, Asia-Pacific/Middle East, Africa, and the United States. The company's corporate office is in Costa Rica, with headquarters in Austin, Texas. Approximately 20% of revenues come from the United States. The company has significant market shares in Switzerland, South Korea and Taiwan.

Establishment Labs Holdings, Inc. has generally maintained a positive brand reputation, particularly within the analyst community. Analysts have largely issued "Buy" or "Outperform" ratings, with an average 12-month price target of $86.8571 as of March 30, 2026. The company's Motiva implants are gaining market share internationally, and its pending FDA approval in the U.S. is seen as a significant growth catalyst. However, there have been historical concerns about the company's claims of superior safety for its implants. More recently, the company's Q4 2025 earnings beat forecasts, but the stock still dropped, which could reflect underlying investor sentiment or concerns not directly tied to product reputation but rather future profitability guidance.

Establishment Labs Holdings, Inc. is primarily owned by institutional shareholders, who hold approximately 66.93% to 91.12% of the company's stock. Insiders own around 18.58% to 20.55%, while retail investors and public companies hold a smaller percentage, ranging from 0.99% to 12.40%. Major institutional owners include JW Asset Management, LLC, Rtw Investments, Lp and Brown Advisory Inc. Key individual owners and insiders include Juan Jose Chacon-Quiros and Nicholas Sheridan Lewin.